CIRM Funded Clinical Trials
First-in-human trial for EPI-321, a novel epigenetic therapy for FSHD targeting D4Z4 epigenome
Disease Area:
Muscular Dystrophy
Trial Sponsor:
Epicrispr Biotechnologies, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A